CAR-T Biotechnology

CAR-T Biotechnology appears to refer to CAR-T (Shanghai) Biotech Co., Ltd., a private China-based biotechnology company focused on cell-based therapies. Publicly available information indicates the company has worked across CAR-T, tumor-infiltrating lymphocyte, and mesenchymal stem cell-related programs, with activity spanning oncology and regenerative medicine. Its disclosed development footprint includes an early Phase 1/2 study of autologous TILs in high-risk recurrent primary hepatocellular carcinoma and separate mesenchymal stem cell programs reported for liver and metabolic indications. The company is not well covered in mainstream English-language corporate sources, so much of the available detail comes from commercial company databases and trial aggregators rather than a robust primary corporate disclosure set.